At the Heart of What Fuels Us - Patient Priority

Ken brings more than 30 years of medical device experience to Foldax, both leading companies and serving on boards. Previously, Ken held board and CEO roles at Compellon, a bioinformatics company that was acquired by Clearsense in 2021, and Reshape Lifesciences, a private medical device company that commercialized minimally-invasive products to treat obesity, acquired by EnteroMedics in 2017. He was President and CEO of MindFrame, Inc. which made devices to treat ischemic strokes. In July 2012, Covidien, the world leader in that market, acquired Mindframe. Earlier, Ken was President and CEO of Orqis Medical, a privately funded company in the congestive heart failure space. Ken raised over $85 million for the company and took it from concept through IDE clinical trials. Before Orqis, Ken spent 16 years in general management positions with Baxter Healthcare Corporation, including President of the Bentley Division and President of New Business Initiatives for the Cardiovascular Surgery Division. He also spent four years in Japan as Managing Director of Baxter Japan Cardiovascular Division. Ken earned his B.S. Mechanical Engineering degree from Cornell University and his M.B.A. from the University of Chicago Booth School of Business and completed the Manufacturing Management Program at General Electric Company.

Frank Maguire has more than 30 years of experience in heart valves, other cardiac surgery products and medical grade polymers. Previously he was CEO of Aortech, a publicly traded UK med tech company with facilities in Australia and the US. Frank was Vice President/General Manager for Edwards Lifesciences Research Medical Division in SLC, UT. Frank came to Utah as an engineer for Symbion, Inc., the developer of the Jarvik Artificial Heart. While working for Symbion he was appointed Vice President/General Manager for its Mitral Medical Division developing and manufacturing the Mitroflow bovine pericardial heart valve in Richmond, BC. Frank earned his B.S. in Economics from SUNY Oneonta and his M.B.A. from Golden Gate University.

Laxmi has over 35 years of experience in the fields of pharmaceuticals and medical devices. He has held prior leadership roles in Edwards Lifesciences, Baxter Healthcare and Glaxo. Laxmi brings with him a wealth of knowledge in commercial operations. After leaving Edwards Lifesciences, he held various leadership positions in startups in cardiovascular, neuro, ortho and robotics markets.

Michele has over 35 years of experience in the medical device industry including consulting and senior management positions in areas of pre-clinical development, regulatory affairs, clinical trial management, quality compliance, and new technology reimbursement. She the President of Lakeshore Medical Device Consulting focusing on assisting early phase medical device startups. Recent experience is in class III cardiovascular and spinal devices, and class II vascular access systems, patient monitoring devices, and electrosurgical instruments. Previously Michele was the Vice President of Regulatory and Clinical Affairs for Applied Spine Technologies where her responsibilities also included serving as the sponsor study director for an international IDE clinical trial for a spine dynamic stabilization device. Michele started her career at US Surgical Corporation (now a division of Covidien). During her 14-year tenure Michele, as Director of Corporate Quality Control, was directly involved in the development and commercialization of hundreds of medical devices including mechanical wound closure products and laparoscopic instruments. Michele received her B.S. degree in biology and chemistry from Western Connecticut State University. She is a member of the Regulatory Affairs Professional Society.

Amy joins Foldax with over 30 years of experience driving commercial strategy in medical device companies. She is a seasoned marketing executive who has played key roles in market development, market expansion, and driving therapies to standard of care. Her track record of success spans across large, small, and start-up companies with a focus on implementing strategies for physician and direct-to-consumer marketing. Amy has a deep background in marketing heart valves, with over 13 years of experience managing the global heart valve portfolio for Baxter/Edwards Lifesciences. She has broad medical device experience with startup device companies in cataract surgery, (WaveTec Vision, acquired by Alcon), non-invasive weight loss (ReShape Medical, acquired by Enteromedics), and lumbar spinal stenosis (Vertos Medical, acquired by Stryker). Prior to joining Foldax, Amy served as Vice President of Marketing and Physician Education for Vertos Medical, where her key opinion leader (KOL) development and commercial strategic leadership helped triple sales in three years during the Covid pandemic. Amy holds a B.S. degree in business from Indiana University, and an M.B.A. from Pepperdine University.

Avi has more than 20 years of experience in the medical device industry. He is a well-established leader with a track record of taking concepts to clinical and ultimately leading to successful global commercial approvals of the technology. Avi has previously worked in leadership positions at Medtronic Cardiovascular, Edwards Lifesciences, Accelerant and Endologix. He has directly led multiple global clinical programs to successful market approvals in US, Canada, EU, Japan and countries in Asia. His passion for clinical research comes from the belief that everyone should have rapid access to safe and effective innovative technologies.

Ryan has more than 20 years of experience in the medical device industry, with expertise in active implantables, surgical tools, device hemocompatibility, patient transport, fluid systems, artificial intelligence and computer vision applications, and robotics and automation. Prior to medical devices, Ryan worked for a decade in the field of composite materials, developing and producing advanced recreation, automotive, and aerospace equipment and processes. He has worked in technical leadership and consultant positions with several companies taking concepts to market and acquisition. A Utah native, Ryan earned B.S., M.S., and Ph.D. degrees in Mechanical Engineering and a B.A. degree in Japanese from the University of Utah.

Atul brings over 25 years of management experience in the medical device and life science industries to Foldax. He has extensive experience ranging from general management to operations and commercialization. Previously, he was the President of InVitro International, an innovative provider of non-animal based human safety testing for a wide range of industries. At Paramit (purchased by Tecan for $1B) he helped commercialize contract design and manufacturing services globally, to both industry leaders and start-up companies in the medical device and life science space. He managed worldwide OEM partnerships and built a distributor network in India for Masimo (IPO); commercialized innovative blood pressure technology at BMEYE (purchased by Edwards LifeSciences); led marketing efforts for a public diagnostic cardiology company, Quinton (merged with Cardiac Science) and helped commercialize P.E.T. (positron emission tomography) and Nuclear Medicine technologies for ADAC (bought by Philips Medical Systems). He also worked as a management consultant for Booz Allen & Hamilton and as an automotive engineer for Altair Engineering (acquired by Siemens for $10B). Atul holds a B.S. in Mechanical Engineering from Indian Institute to Technology, an M.S. in Mechanical Engineering from The Ohio State University and an M.B.A from the University of Chicago Booth School of Business.

Dr. Grainger is a University Distinguished Professor and Department Chair of Biomedical Engineering, and Distinguished Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah.  His research expertise is focused on improving implanted medical device performance, drug delivery of therapeutic molecules, biotechnology agents, and live vaccines, nanomaterials interactions with human tissues, antimicrobial biomaterials, and innovating diagnostic devices based on DNA and protein biomarker capture.  Additionally, he is an expert in applications of surface analytical methods to biomedical interfaces, including analytical methods development for difficult organic surface patterns and nanomaterials, and also internationally recognized as an expert of perfluorinated thin films and biomaterials.  He has several successful experiences producing innovative, marketed medical technology.  Dr. Grainger received his B.A. in engineering and chemistry from Dartmouth College, Ph.D. in Pharmaceutical Chemistry from the University of Utah and performed postdoctoral research in interfacial chemistry and biophysics at the University of Mainz, Germany.

Dr. Padsalgikar is a widely known and well-respected expert in the field of long term implantable medical polymers. His areas of expertise include polymer reaction engineering, chemistry, structure and property and processing. He is named in 25+ publications and recently authored the textbook Applications of Polyurethanes in Medical Devices, May 2022 as part of the PDL Plastics Design Library series. He is a named inventor on 12 patents which include silicone urethane compositions. Dr. Padsalgikar has held Chief Scientific Officer and Principal Scientist positions at AorTech, St. Jude Medical/Abbott and DSM. In these roles has interacted with FDA on long term stability of polymers. Dr. Padsalgikar did his B. Eng. at Maharashtra Institute of Technology and his Ph.D. in Polymer Science at Clemson University.

Chris Jenney is an applied materials and biomaterials expert, having over 20 years of experience in the implantable medical device field.  Chris was instrumental in the development and testing of the first commercially released, implantable, cardiac stimulation leads designed with silicone-polyurethane insulation.  Chris is an expert in material selection, processing methods, and material characterization, including physical, chemical, thermal, and imaging methods.  Chris’ industry experience includes drug eluting combination devices, implantable pacing and defibrillation leads, neuromodulation systems, and microelectronics.  Chris brings practical expertise in the areas of biocompatibility, mechanisms of implantable device failure, and material degradation pathways. Chris received his B.S. in Materials Engineering from California Polytechnic State University, San Luis Obispo and Ph.D. in Biomedical Engineering from Case Western Reserve University.

Dr. Ajit Yoganathan is the Wallace H. Coulter Distinguished Chair in Biomedical Engineering & Regents’ Professor in the Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, and a member of prestigious U.S. National Academy of Engineering. He has been a pioneer in basic and translational cardiovascular research in fluid mechanics as they pertain to artificial heart valves, the whole heart, and congenital heart diseases. His work utilizes optical techniques (laser Doppler velocimetry & digital particle image velocimetry), as well as clinical tools (cardiac U/S & MRI to non-invasively study and quantify blood flow patterns and parameters in the cardiovascular system, both on the bench and in vivo. Over the last 45 years, Dr. Yoganathan’s contributions to the improvements of the biomechanics of prosthetic heart valves and heart valve repairs have been profound – since 1975, all prosthetic heart valves for use in the U.S. have been evaluated his lab. He received his B.S. in chemical engineer from University College, University of London and Ph.D. in chemical engineering the California Institute of Technology.

Dr. McCarthy is the Chief Scientific Officer at Tricol Biomedical. He brings over 25 years of research experience in chemistry and holds multiple worldwide patents in the chemistry and medical device field. He joined HemCon in 2001 as one of the primary founders and inventors of the underlying technology utilized in the lifesaving HemCon wound care solutions. Simon was named by the US Army as a Top Ten Invention Award recipient in 2005 for invention & development of the HemCon Chitosan Bandage. He further won the Tibbets Award in 2007 for the HemCon Bandage and was the finalist in Australia Eureka Awards 2012 for development of the novel co-polyurethane-siloxane Elast-Eon. Dr. McCarthy received his B.S. in mathematics, computer science and chemistry and Ph.D. in physical & polymer chemistry from Monash University.

Dr. Gunatillake was a Chief Research Scientist and currently a Fellow at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Melbourne, Australia.  He is a leading biomaterial scientist with world-wide reputation in the field of polyurethanes. His research has been and continues to be design and synthesis of polymers for biomedical applications. He has successfully made the transition from basic discovery research through the entire product development pipeline and helped delivery of commercial products into the medical device marketplace. He has received international recognition through technology innovations and valuable literature contributions to the understanding of structure-property relationships of polyurethanes and their effect on biostability/biodegradability. Dr. Gunatillake received his B.S. in chemistry from the University of Ceylon, M.Phil. in chemistry and Ph.D. in polymer chemistry from City University of New York.

James Runt is Professor Emeritus of Polymer Science in the MatSE Department at Penn State University. His research interests focus on the relationship between polymer dynamics and nanoscale phase separation, and how these influence macroscopic properties and performance of multiphase polymer systems. He is a Fellow of the American Physical Society and the American Institute of Medical and Biological Engineers. He was a co-editor of an ACS Symposium Series book: Polymers for Energy Storage and Delivery: Polyelectrolytes for Batteries and Fuel Cells, and an editor of the ACS Professional Reference Series book: Dielectric Spectroscopy of Polymeric Materials: Fundamentals and Applications. Dr. Runt received his B.S. in Materials Science and Engineering and Ph.D. in Solid State Science with a concentration in polymeric materials from Pennsylvania State University.

Dr. Mack is Medical Director of Cardiovascular Surgery for the Baylor Health Care System in Texas. He is Chairman of The Heart Hospital Baylor Plano Research Center. His areas of specialty include cardiothoracic surgery, heart valve replacement and repair and transcatheter aortic valve replacement (TAVR). Dr. Mack is Board certified in cardiothoracic surgery and internal medicine. Dr. Mack completed medical school at St. Louis University School of Medicine and performed his general surgery and thoracic surgery residencies at University of Texas Southwestern Medical School.

Dr. Kiser has pioneered innovative approaches to heart surgery that are transforming the treatment of certain heart conditions, including atrial fibrillation, a disorder of the heart’s rhythm, as well as valve and coronary disease. He conceived and developed the innovative convergent hybrid ablation procedure for the treatment of persistent atrial fibrillation, the most common heart rhythm disturbance and a leading cause of stroke. He also has extensive experience in the surgical treatment of cardiac valve disease and coronary artery disease, and as a thoracic surgeon, in the treatment of diseases of the lungs, chest wall and esophagus, including cancers. Dr. Kiser is a Fellow of the American College of Surgeons, the American College of Cardiology and the American College of Chest Physicians. Dr. Kiser is the founder and CEO of Advanced Cardiac Access Training Institute in North Carolina, which has provided education and advanced training in surgical skills and procedural simulation to other surgeons across the United States and around the world. Dr. Kiser has authored numerous scientific papers and textbook chapters on cardiothoracic surgery and a wide range of other topics.

Dr. Brian Whisenant is the Medical Director of Valve and Structural Heart Disease at Intermountain Medical Center. He is a distinguished Cardiologist and Interventional Cardiologist based in Murray, Utah. Renowned for his expertise in treating complex cardiovascular conditions, Dr. Whisenant is highly rated across 18 different conditions. His primary areas of focus include Mitral Valve Regurgitation, Mitral Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement. With a strong foundation from Columbia University College of Physicians and Surgeons, Dr. Whisenant has made significant contributions to the field of cardiology. Over the past 15 years, he has co-authored 118 peer-reviewed articles and actively participated in 13 clinical trials, underscoring his commitment to advancing cardiovascular care. Dr. Whisenant holds a license in Internal Medicine in Utah and is board-certified in Cardiology, Interventional Cardiology, and Cardiac Electrophysiology. His dedication to patient care and clinical research continues to make a profound impact in the field of cardiology.

Dr. Isaac George, MD joined NewYork Presbyterian/Columbia University Medical Center in the Department of Surgery in July of 2001 as a resident in general surgery following his graduation from Duke University School of Medicine. Prior to receiving his MD, Dr. George completed a B.S. in Mechanical Engineering at Massachusetts Institute of Technology in 1997. Dr. George also completed a fellowship program in cardiothoracic surgery in 2011 as well as a fellowship program in interventional cardiology in 2012. Dr. George is an Associate Professor of Surgery and Medicine, and the Surgical Director of Structural Heart of the NYP health system. Dr. George is board certified in thoracic (cardiac) surgery. He performs all types of open and reoperative adult cardiac surgery (aortic, mitral and tricuspid valve surgery, aortic aneurysm surgery, coronary bypass grafting, robotic surgery) with a particular interest in complex valvular disease. He specializes in minimally invasive mitral valve surgery with small incisions and repair of the mitral valve. He annually performs 150-200+ open heart surgeries a year and is the busiest heart surgeon by procedure volume in New York State. Dr. George is currently the Co-Director of the Structural Heart and Valve Center at Columbia University Medical Center. His surgical outcomes remain some of the best in the state despite taking on the highest risk cases (surgical mortality rate per year ~1.5%).

Dr. Answini is the Chief, Division of Cardiothoracic Surgery and Co-Director of Cardiovascular Service Line at The Christ Hospital in Cincinnati, Ohio. He is a board-certified cardiothoracic surgeon and one of the few cardiac surgeons in the Greater Cincinnati area who performs complex open and endovascular aortic surgery. His clinical specialty is minimally invasive surgery, including valves, LVADS, and endovascular surgery (including EVAR, TEVAR, and TAVR). He has participated in more than 40 clinical trials and has authored several articles in peer-reviewed medical journals. He has presented his work at conferences and symposia including the annual meetings of the American College of Surgeons and the World Surgical Congress of Endoscopic Surgery. After graduating magna cum laude from Auburn University, AL, where he was an All-American swimmer, Dr. Answini earned his medical degree at Temple University School of Medicine, Philadelphia, PA. He completed a surgical residency at Carolinas Medical Center, Charlotte, NC, followed by a cardiothoracic surgery residency with extensive exposure to endovascular therapies at St. Louis University Hospital, MO. He joined the Ohio Heart and Vascular Center at The Christ Hospital in 2003.

Dr. Leon is Professor of Medicine at Columbia University Irving Medical Center (CUIMC). Dr. Leon is also Director of Columbia Interventional Cardiovascular Care, Director of the Cardiac Catheterization Laboratories, and is on the Executive Board of the Columbia Structural Heart & Valve Center. He is a practicing interventional cardiologist at New York-Presbyterian Hospital in New York City. Dr. Leon is also the Founder and Chairman Emeritus of the Cardiovascular Research Foundation. Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine. Dr. Leon has co-authored over 1550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in the expanding sub-specialty of interventional cardiovascular device and drug therapies. He is the Director and Founder of Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier interventional cardiovascular meeting. Dr. Leon has also served as Director or Co-Director of more than 100 international educational programs in areas of interventional cardiology. Dr. Leon completed a fellowship in Cardiology at the Yale-New Haven Hospital. He completed medical school at the Yale School of Medicine, and his internship and residency in internal medicine at the Yale-New Haven Hospital.

Dr. Yakubov is the John H. McConnell Chair of Advanced Structural Heart Disease, System Medial Chief, Advanced Structural Heart Disease of OhioHealth and Medical Director of Cardiovascular Studies for the OhioHealth Research Institute at Riverside Methodist Hospital, Columbus, Ohio. He has been involved in numerous clinical trials to advance treatment options for cardiovascular disease and structural heart disease. He is a speaker at several annual major cardiovascular conferences and has numerous publications in major medical journals and book chapters. He has been instrumental in the development of new technology for the treatment of structural heart disease. Dr. Yakubov received his medical degree from the Northeast Ohio Medical University NEOMED (formerly known as NEOUCOM), completed his Internal Medicine residency at Riverside Methodist Hospital and completed his cardiology fellowship at the University of Michigan.

Dr. Matthew is the Director of the Cardiac Catheterization Laboratory at Keck Medical Center of the University of Southern California and Professor of Clinical Medicine at the University of Southern California. He is widely known as a leader in interventional cardiology and has served as principal investigator for more than 50 clinical trials researching new devices. He is also a pioneer in many interventional procedures that are now commonplace in the catheterization lab. Dr. Matthews received his bachelor’s degree in biochemistry from University of Wyoming and medical degree from Creighton University, completed his internal medicine residency at the Mayo Clinic. He later completed a general cardiology fellowship at Harbor-UCLA Medical Center and an interventional cardiology fellowship at Good Samaritan Hospital in Los Angeles.

Mr. Heise leads the investing activities of MemorialCare investment fund. Over the last 30+ years, Mr. Heise has accumulated a broad range and scope of healthcare experience within both the non-profit and for-profit arenas. His accomplishments include business development and operating experience in entrepreneurial start-up companies, physician organizations, community hospitals and academic medical centers. Mr. Heise’s experience also includes participation on the Board of Directors for over 30 privately held, venture capital funded companies. In addition to his role at MemorialCare Innovation Fund, Mr. Heise is also Senior Managing Director at Summation Health Ventures and Vice President at National Healthcare Services. Prior to those rolls, Mr. has held several operational rolls with several start-up companies (Geritrix, ForHealth, and Cornerstone Physicians Corporation) and was clinical administrator at Los Angeles County and University of Southern California Medical Center. Mr. Heise earned a Masters of Healthcare Service Administration from the University of Michigan, as well as a Bachelor of Arts in Psychology from Grinnell College.

George Wallace is a seasoned entrepreneur and executive with over three decades of experience in building and leading innovative medical device companies. His expertise spans executive leadership, strategic investments, and commercialization of groundbreaking healthcare technologies. Currently serving as Chief Executive Officer at EnCompass Technologies, Inc., George has been at the helm since 2018, driving innovation and growth in the medical technology sector. Prior to this, he spent 20 years as Managing General Partner of Intersect Partners, a firm focused on research and investment in solutions for large, unmet medical needs in healthcare. George co-founded and served as President and CEO of two successful ventures: Sub-Q, Inc., which developed advanced closure technologies for puncture sites, and Micro Therapeutics, Inc., a pioneer in neurovascular intervention acquired by ev3. His leadership was instrumental in developing and marketing transformative products that addressed critical gaps in patient care. Earlier in his career, George held leadership roles at Applied Medical, where he served as General Manager across multiple divisions, gaining extensive operational and sales experience.

Jim Demetriades is the Founder & CEO of Kairos Ventures, a venture capital firm that partners with universities to identify the world’s leading scientific discoveries and commercialize them. Kairos, which Jim founded in 2015, is currently invested in more than 50 portfolio companies that are producing groundbreaking technologies with the potential to disrupt the industries in which they operate. Jim’s fervent belief is that the discoveries Kairos is bringing to life will not only improve lives, but also, ultimately, help restore a sense of hope. Prior to founding Kairos, Jim founded SeeBeyond Technology Corp. in 1989 which he built into the world’s largest organically grown and self-funded integration software company whose technologies were used by thousands of global customers ranging from Fortune 500 companies to large hospitals and healthcare systems. Under Jim’s leadership, SeeBeyond grew to over 1,600 employees with offices in 35 countries. After taking SeeBeyond public, the company was acquired in an all-cash transaction by Sun Microsystems (now part of Oracle) in 2005 for almost $400 million. Jim also founded real estate development and management company, Multiversal, and his own unique children’s internet education media company, Inspero.net. He is currently on the boards of numerous technology companies across a variety of industries and is a Board Member of the Jane Goodall Legacy Foundation. He holds a Bachelor of Science degree in Economics, with a second major in computer science and minors in marketing and mathematics from Loyola Marymount University, Los Angeles.

Ken brings more than 30 years of medical device experience to Foldax, bothleading companies and serving on boards. Previously, Ken held board and CEO roles at Compellon, a bioinformatics company that was acquired by Clearsense in 2021, and Reshape Lifesciences, a private medical device company that commercialized minimally-invasive products to treat obesity, acquired by EnteroMedics in 2017. He was President and CEO of MindFrame, Inc. which made devices to treat ischemic strokes. In July 2012, Covidien, the world leader in that market, acquired Mindframe. Earlier, Ken was President and CEO of Orqis Medical, a privately funded company in the congestive heart failure space. Ken raised over $85 million for the company and took it from concept through IDE clinical trials. Before Orqis, Ken spent 16 years in general management positions with Baxter Healthcare Corporation, including President of the Bentley Division and President of New Business Initiatives for the Cardiovascular Surgery Division. He also spent four years in Japan as Managing Director of Baxter Japan Cardiovascular Division. Ken earned his B.S. Mechanical Engineering degree from Cornell University and his M.B.A. from the University of Chicago Booth School of Business and completed the Manufacturing Management Program at General Electric Company.

Fred Farina is Caltech’s Chief Innovation and Corporate Partnerships Officer. His responsibilities include commercializing inventions made at Caltech and the Jet Propulsion Laboratory (JPL/NASA) through the creation of new startup ventures and partnerships with established companies. His office is responsible for evaluating inventions, supervising patent prosecution and portfolio management, negotiating licensing deals with industry, assisting Caltech/JPL entrepreneurs with the creation of new startup companies and establishing research collaborations with industry. Prior to joining the office, Frederic worked as a research engineer in the GPS field at JPL and the University of Miami. He subsequently joined a law firm where he prosecuted patent applications on various technologies before the U.S. and European patent offices. Fred holds a "Diplôme d'Ingénieur" in Electrical Engineering from the Institut National des Sciences Appliquees, Lyon, France, and is a graduate of Caltech from which he received a Master’s degree in Electrical Engineering in 1992. He is a registered patent agent with the U.S. Patent and Trademark Office.